Naslov
Management of abemaciclib side effects in clinical practice – case report

Autori
Kanceljak, Kristina ; Lepetić, Petra ; Linarić, Petra ; Tečić Vuger, Ana ; Vazdar, Ljubica ; Pavlović, Mirjana ; Šeparović, Robert

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Skup
1st Croatian virtual congress of oncology pharmacy

Mjesto i datum
Online, 07.10.2021. - 10.10.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
breast cancer, CDK4/6 inhibitors, abemaciclib, diarrhea

Sažetak
CDK4/6 inhibitors have shown very good results in combination with antihormonal therapy in advanced breast cancer - leading to FDA approval of palboci¬clib, ribociclib and most recently abemaciclib. MONARCH 2 was a global, multicenter, double-blind, randomized (2:1), placebo-controlled phase 3 study of abemaciclib plus fulvestrant vs placebo plus fulvestrant in women with HR-positive and HER2-negative advanced breast cancer who progressed during antihormonal therapy. This study demonstrated that the addition of abemaciclib to fulvestrant resulted in a statistically significant improvement in overall survival (median OS improvement of 9.4 months).We report a case of advanced breast cancer treated with abemaciclib plus fulvestrant resulting in reducing the dose due to severe side effects.Our case shows how good communication and tools assessing patient needs as well as prompt reaction to debilitating AEs can result in a stabilization of situation and good, prolonged treatment duration, in order to reach for a maximum of a life-prolonging treatment.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA